Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 10;12(4):152.
doi: 10.3390/ph12040152.

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I

Affiliations
Review

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I

Raquel Vieira et al. Pharmaceuticals (Basel). .

Abstract

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

Keywords: diabetes mellitus; glucose-lowering agents; metabolic syndrome; phytotherapy; sugar-lowering oils.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main characteristics of pancreatic function in healthy individuals versus in diabetic individuals. In heathy individuals, the pancreas responds to hyperglycaemia with insulin secretion aiming to maintain gluco-homeostasis. Diabetes occurs when the pancreas fails to produce insulin, DMT1, insulin-dependent, or when insulin produced is insufficient or unable to produce gluco-homeostasis (DMT1).
Figure 2
Figure 2
Oral and injectable non-insulin glucose-lowering drugs approved by the American Diabetes Association.

References

    1. Porth C.M. Essentials of Pathophysiology: Concepts of Altered Health States. 3rd ed. Volume 3. Wolters Kluwer; Alphen aan den Rijn, The Netherlands: Oct 15, 2010. ISBN-10 1582557241; ISBN-13 978-1582557243.
    1. Timper K., Donath M.Y. Diabetes mellitus Type 2—The new face of an old lady. Swiss Med. Wkly. 2012;142:w13635. doi: 10.4414/smw.2012.13635. - DOI - PubMed
    1. Nogueira C., Souto S.B., Vinha E., Braga D.C., Carvalho D. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones (Athens) 2013;12:483–494. doi: 10.14310/horm.2002.1436. - DOI - PubMed
    1. Souto S.B., Souto E.B., Braga D.C., Medina J.L. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM) Eur. J. Clin. Pharmacol. 2011;67:653–661. doi: 10.1007/s00228-011-1038-z. - DOI - PubMed
    1. Vieira R., Souto S.B., Sanchez-Lopez E., Machado A.L., Severino P., Jose S., Santini A., Silva A.M., Fortuna A., Garcia M.L., et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II. J. Clin. Med. 2019;8:1332. doi: 10.3390/jcm8091332. - DOI - PMC - PubMed